Response to Comments: MolDX: Molecular Assays for the Diagnosis of Cutaneous Melanoma

This document is a response to public comments on MolDX Local Coverage Determination DL39373 for molecular assays diagnosing cutaneous melanoma and does not itself define clinical coverage criteria. It records the comment period (07/07/2022–08/20/2022), notice period beginning 06/22/2023, and the LCD effective date of 08/06/2023. For specific coverage indications, limitations, documentation, and frequency limits, refer to LCD DL39373 (MolDX: Molecular Assays for the Diagnosis of Cutaneous Melanoma).